CARL Carlsmed, Inc.

BUSINESS SUMMARY

Carlsmed makes AI-personalized spinal implants and surgical-planning software for adult spinal-deformity surgery. The product is the aprevo platform: pre-operative imaging is fed into Carlsmed's modeling engine, an individualized titanium interbody implant is 3D-printed for that specific patient's anatomy, and the surgical plan is delivered to the operating surgeon.

The customer is the hospital and the surgeon, not the patient. Revenue is per-case: the personalized implant + planning service is sold per procedure, with reimbursement flowing through hospital DRG payments and a transitional pass-through code from CMS in the US.

Carlsmed IPO'd in 2024. Adult spinal-deformity surgery is a small but high-acuity segment of the broader spine market — the sub-population where personalized planning has the clearest clinical case versus stock implants from larger competitors.

MARKET OPPORTUNITY

The US spine-implant market is dominated by Medtronic, Stryker, Globus Medical, and NuVasive. Carlsmed plays specifically in the adult spinal-deformity sub-segment — typically older patients with scoliosis or sagittal-imbalance complications who need multi-level reconstruction.

Where Carlsmed is exposed:

• Surgeon-led adoption — each surgeon trained on aprevo becomes a multi-year revenue stream as their personal case mix shifts toward the platform
• CMS transitional pass-through payment provides reimbursement clarity for hospital sites — without it, hospital uptake stalls because traditional spine implants are bundled into the DRG
• Outcome-data flywheel — every procedure feeds outcomes back into the planning model

Macro context: the spine-deformity market grows mid-single-digit organically; Carlsmed's growth is therefore mostly share-take from generic implants, not market-expansion. The platform has to be sufficiently better than off-the-shelf for surgeons to switch.

REVENUE QUALITY

The numbers reflect a high-priced personalized-medical-device launch:

• Gross margin 75.5% — high for a medical device; reflects the personalized-software content baked into the per-case price
• Operating margin negative — commercial-team and surgeon-training buildout is the largest expense
• Revenue growth 85.7% YoY on $51M TTM — early commercial S-curve, which typically lasts 8-12 quarters before deceleration
• P/S ~5 — premium for a med-device name; only justified if surgeon-adoption keeps compounding

What hides in the data: per-case revenue is high (low-five-figures range), so quarterly numbers move sharply with surgeon-trained-count and per-surgeon case-volume. Investors should track these two leading indicators rather than just dollar revenue, since the unit-count signal arrives a quarter before the revenue impact.

COMPETITIVE ADVANTAGE

The defensible asset is the personalized-planning data and the surgeon training pipeline:

• Outcomes data per case is proprietary and grows monotonically — competitors cannot replicate the dataset by buying it
• Surgeon-training certification creates switching costs once a surgeon has done 10-20 aprevo cases
• CMS pass-through code for the device class is a reimbursement-relationship moat that takes years to establish

What it is not: a moat against Medtronic or Stryker if they decide to launch their own personalized-implant program. Both have the engineering, manufacturing, and distribution to copy the model. Carlsmed's race is to lock in surgeon-relationships and clinical-outcome data before the incumbents move.

GROWTH THESIS

Three pieces have to work:

1. Surgeon-adoption keeps compounding. Each new aprevo-trained surgeon is a multi-year recurring revenue source; if the trained-surgeon count stalls, growth caps mechanically.
2. Per-surgeon case-volume ramps. Trained surgeons start at 1-2 cases/quarter; the question is whether they reach 4-6+ as comfort grows.
3. CMS reimbursement remains favorable. Pass-through codes are time-limited and renewal is not guaranteed — a CMS unfavorable decision would directly hit per-case economics.

KEY RISKS

Three specific risks:

1. Big-spine entry. Medtronic, Stryker, or Globus building their own personalized-implant offering would force Carlsmed to compete on distribution and pricing where it has structural disadvantage. The clock is real.

2. Reimbursement reversal. CMS transitional pass-through is finite-duration and subject to re-evaluation. An unfavorable rate-setting decision would compress per-case revenue without anything changing on the clinical side.

3. Single-indication concentration. Almost all revenue is adult spinal-deformity. Expanding to additional indications (degenerative disease, deformity in other anatomical regions) is a multi-year clinical and regulatory project that the current growth-rate doesn't yet reflect.

VERDICT

The 89.4/100 score correctly captures the launch-stage growth, software-like gross margin, and clean balance sheet. What it under-weights is competitive-fragility against vertically-integrated giants — the moat is real today but not durable against a motivated entrant.

For investors who want exposure to AI-driven medical-device commercialization at small-cap scale, CARL is one of the cleaner names. For investors needing diversified product portfolios or scale-protected competitive position, this is too narrow.

The single metric to watch next is trained-surgeon count and procedures-per-trained-surgeon, both disclosed in earnings calls. If both compound, the surgeon-relationship-moat thesis is intact. If trained-count slows, the network-effect window is closing.